FTC expert says drugmakers’ settlement evolved too fast

The Federal Trade Commission’s expert witness said on Tuesday that a 2010 co-promotional agreement between Impax and rival drugmaker Endo was highly unusual because the agreement to pay Impax $10 million to develop a Parkinson’s drug occurred after only one month of negotiations.

Get unlimited access to all Global Competition Review content